AR093481A1 - Parche de varios dias para la administracion transdermica de rotigotina - Google Patents
Parche de varios dias para la administracion transdermica de rotigotinaInfo
- Publication number
- AR093481A1 AR093481A1 ARP130104186A ARP130104186A AR093481A1 AR 093481 A1 AR093481 A1 AR 093481A1 AR P130104186 A ARP130104186 A AR P130104186A AR P130104186 A ARP130104186 A AR P130104186A AR 093481 A1 AR093481 A1 AR 093481A1
- Authority
- AR
- Argentina
- Prior art keywords
- rotigotine
- transdermal therapeutic
- therapeutic system
- self
- adhesive matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B37/00—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
- B32B37/12—Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by using adhesives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2556/00—Patches, e.g. medical patches, repair patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sistema terapéutico transdérmico, que comprende: (a) una capa de refuerzo; (b) una capa matriz autoadhesiva a base de disolvente que contiene rotigotina como ingrediente activo; y (c) un protector antiadherente, donde la capa matriz autoadhesiva tiene un peso del recubrimiento de aproximadamente 75 - 400 g/m² y comprende una capa de depósito que contiene aproximadamente entre 9 y 25% en peso de rotigotina sobre la base del peso de la capa de depósito; un kit que comprende dos sistemas terapéuticos transdérmicos de la presente, así como un método para la preparación del sistema terapéutico transdérmico de la presente. Sistema terapéutico transdérmico que comprende rotigotina como ingrediente activo para su uso en el tratamiento de pacientes que sufren de enfermedad de Parkinson, síndrome de Parkinson plus, depresión, fibromialgia y síndrome de las piernas inquietas; y para su uso en el tratamiento o la prevención de la pérdida de neuronas dopaminérgicas o trastornos cognitivos mediante la administración transdérmica de rotigotina una vez o dos veces por semana, donde el sistema terapéutico transdérmico comprende una capa de refuerzo, una capa matriz autoadhesiva que contiene rotigotina a base de disolvente, así como un protector antiadherente, y está adaptado para permitir la administración transdérmica de cantidades terapéuticamente eficaces de rotigotina durante al menos 3 días.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12193808 | 2012-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093481A1 true AR093481A1 (es) | 2015-06-10 |
Family
ID=47215446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104186A AR093481A1 (es) | 2012-11-22 | 2013-11-14 | Parche de varios dias para la administracion transdermica de rotigotina |
Country Status (15)
Country | Link |
---|---|
US (2) | US11389410B2 (es) |
EP (1) | EP2922533B1 (es) |
JP (1) | JP6301356B2 (es) |
KR (1) | KR20150094588A (es) |
CN (2) | CN104736146B9 (es) |
AR (1) | AR093481A1 (es) |
AU (1) | AU2013350037B2 (es) |
BR (1) | BR112015011729B1 (es) |
CA (1) | CA2887085C (es) |
EA (1) | EA201500553A1 (es) |
ES (1) | ES2639294T3 (es) |
IN (1) | IN2015DN02488A (es) |
MX (1) | MX354502B (es) |
TW (1) | TW201431570A (es) |
WO (1) | WO2014079573A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
CN105358139B (zh) | 2013-07-03 | 2020-10-16 | Lts罗曼治疗方法有限公司 | 具有电子元件的经皮治疗系统 |
CA2948219C (en) | 2014-05-20 | 2023-04-04 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
CN106456566B (zh) * | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
EP4238580A3 (en) * | 2014-05-20 | 2023-10-25 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system including an interface mediator |
AR098771A1 (es) * | 2014-12-16 | 2016-06-15 | Amarin Tech S A | Un dispositivo para la administración transdérmica de rotigotina |
JPWO2018199015A1 (ja) * | 2017-04-26 | 2020-03-12 | ニプロ株式会社 | 経皮吸収型製剤およびその製造方法 |
WO2018199018A1 (ja) * | 2017-04-26 | 2018-11-01 | ニプロ株式会社 | 経皮吸収型製剤およびその製造方法 |
BR112020003314A2 (pt) * | 2017-09-04 | 2020-08-25 | Lts Lohmann Therapie-Systeme Ag | sistema de liberação transdérmico incluindo um emulsificante |
DE102018120505A1 (de) * | 2017-10-20 | 2019-04-25 | Amw Gmbh | Verhinderung der Kristallisation von Wirkstoffen in transdermalen Darreichungssystemen |
BR112020026099A2 (pt) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | sistema terapêutico transdérmico que contém asenapina |
KR102574287B1 (ko) * | 2018-10-01 | 2023-09-01 | 히사미쯔 제약 주식회사 | 아세나핀 함유 첩부제 |
KR20200046461A (ko) * | 2018-10-24 | 2020-05-07 | 에스케이케미칼 주식회사 | 비결정 로티고틴 함유 조성물 및 이의 제조 방법 |
JP7129501B2 (ja) * | 2019-02-15 | 2022-09-01 | 久光製薬株式会社 | ロチゴチン安定化方法 |
KR102401412B1 (ko) * | 2019-06-14 | 2022-05-23 | 히사미쓰 세이야꾸 가부시키가이샤 | 로티고틴 함유 첩부제 |
KR102260202B1 (ko) * | 2019-10-30 | 2021-06-03 | 에바바이오 주식회사 | 로티고틴 공융 혼합물 및 이의 용도 |
CN113613637A (zh) * | 2019-12-20 | 2021-11-05 | 罗曼治疗系统股份公司 | 含有阿戈美拉汀的经皮治疗系统 |
PT3854388T (pt) * | 2020-01-24 | 2023-12-11 | Luye Pharma Switzerland Ag | Sistema terapêutico transdérmico com o princípio ativo rotigotina e pelo menos um adesivo de silicone não resistente a aminas |
CN113384560A (zh) * | 2021-07-07 | 2021-09-14 | 华健医疗(深圳)有限公司 | 一种治疗或预防神经系统疾病的罗替戈汀与尼古丁的复方透皮贴片及制备方法 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3315272C2 (de) * | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
US4906463A (en) | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US5300291A (en) | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
US4994267A (en) | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
US5032207A (en) | 1988-03-04 | 1991-07-16 | Noven Pharmaceuticals, Inc. | One-step method for forming a pressure-sensitive adhesive transdermal drug device |
US4814168A (en) | 1988-03-04 | 1989-03-21 | Noven Pharmaceuticals, Inc. | Transdermal multipolymer drug delivery system |
US5405486A (en) | 1988-03-04 | 1995-04-11 | Noven Pharmaceuticals, Inc. | Apparatus for forming a transdermal drug device |
WO1991014463A1 (en) | 1990-03-28 | 1991-10-03 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4994278A (en) | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Breathable backing |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
AU2004092A (en) | 1991-04-25 | 1992-12-21 | Noven Pharmaceuticals, Inc. | Method and apparatus for forming a transdermal drug device |
US5387189A (en) | 1993-12-02 | 1995-02-07 | Alza Corporation | Electrotransport delivery device and method of making same |
US6449319B1 (en) | 1998-03-20 | 2002-09-10 | Koninklijke Philips Electronics N.V. | Receiver with a clock signal generator |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
US6757560B1 (en) | 1999-04-09 | 2004-06-29 | Novosis Pharma Ag | Transdermal delivery system (TDS) with electrode network |
US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6317630B1 (en) | 1999-01-29 | 2001-11-13 | Yossi Gross | Drug delivery device |
JP4412874B2 (ja) | 1999-06-08 | 2010-02-10 | アルテア セラピューティクス コーポレイション | 薄膜組織インターフェイスデバイスを使用する生物学的膜のミクロポレーションのための装置、およびそのための方法 |
ES2194736T3 (es) | 1999-07-02 | 2003-12-01 | Lohmann Therapie Syst Lts | Sistema de microdepositos sobre la base de polisiloxanos y disolvente ambifilos. |
DE10012908B4 (de) | 2000-03-16 | 2005-03-17 | Lts Lohmann Therapie-Systeme Ag | Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung |
DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
MXPA03008999A (es) | 2001-04-02 | 2004-02-12 | Astrazeneca Ab | Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp. |
DE10118282A1 (de) | 2001-04-12 | 2002-12-05 | Lohmann Therapie Syst Lts | Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke |
EP1256339B1 (en) * | 2001-05-08 | 2003-10-15 | Schwarz Pharma Ag | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
SI1256340T1 (en) | 2001-05-08 | 2003-12-31 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of Parkinson's disease |
DE10141651B4 (de) * | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
US7247315B2 (en) | 2001-08-17 | 2007-07-24 | Lavipharm Laboratories Inc. | Compositions and medical device for transdermal delivery of a drug and methods of making and using same |
DE10159745A1 (de) | 2001-12-05 | 2003-07-03 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort |
US6775570B2 (en) | 2002-02-04 | 2004-08-10 | Ceramatec, Inc. | Iontophoretic treatment device |
US20030180281A1 (en) | 2002-03-11 | 2003-09-25 | Bott Richard R. | Preparations for topical skin use and treatment |
US20060263419A1 (en) | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
DE10220230A1 (de) | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
EP1386605A1 (en) | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
EP1386604A1 (en) | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
ATE295726T1 (de) | 2002-12-02 | 2005-06-15 | Sanol Arznei Schwarz Gmbh | Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese |
DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
US7603144B2 (en) | 2003-01-02 | 2009-10-13 | Cymbet Corporation | Active wireless tagging system on peel and stick substrate |
JP2006515952A (ja) | 2003-01-02 | 2006-06-08 | シンベット・コーポレイション | ソリッドステートのバッテリー給電の装置と製法 |
WO2004089361A1 (en) | 2003-04-14 | 2004-10-21 | Lts Lohmann Therapie-Systeme Ag | Therapeutic patch with polysiloxane matrix comprising capsaicin |
US20050019385A1 (en) * | 2003-07-21 | 2005-01-27 | Noven Pharmaceuticals, Inc. | Composition and method for controlling drug delivery from silicone adhesive blends |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
US9205062B2 (en) | 2004-03-09 | 2015-12-08 | Mylan Pharmaceuticals, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
US20050202073A1 (en) | 2004-03-09 | 2005-09-15 | Mylan Technologies, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
ES2301017T3 (es) | 2004-05-28 | 2008-06-16 | Jan De Geest | Unidad de comunicacion para la piel de una persona. |
JP2006178807A (ja) | 2004-12-24 | 2006-07-06 | Echigo Fudagami Kk | Icシート製造装置及びicシート製造方法 |
GB0506139D0 (en) | 2005-03-24 | 2005-05-04 | Transphase Ltd | A transdermal topical composition and its uses |
TWI389709B (zh) | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
DE102006054733A1 (de) | 2006-11-21 | 2008-05-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit |
CN101147739B (zh) | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂 |
JP2010536434A (ja) | 2007-08-17 | 2010-12-02 | イシス バイオポリマー エルエルシー | イオン泳動薬物送達システム |
US20100311661A1 (en) | 2007-08-24 | 2010-12-09 | Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of compounds derived from cycloheximide for the treatment or prevention of, in particular, ischaemias and cardiopathies |
CL2008003092A1 (es) | 2007-10-19 | 2009-11-27 | Abbott Gmbh & Co Kg | Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende . |
WO2009068520A2 (en) | 2007-11-28 | 2009-06-04 | Schwarz Pharma Ag | Polymorphic form of rotigotine |
JP5695562B2 (ja) | 2008-05-30 | 2015-04-08 | マイラン・インコーポレーテッド | 安定化された経皮薬物送達システム |
JP2009297808A (ja) | 2008-06-11 | 2009-12-24 | Chiyoda Integre Co Ltd | 粘着テープ製造方法及び粘着テープ製造装置 |
EP2140861A1 (en) | 2008-06-30 | 2010-01-06 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising polymeric carrier composition |
AR074047A1 (es) | 2008-09-09 | 2010-12-22 | Transcu Ltd | Sistemas, dispositivos, y metodos para suministrar energia a dispositivos, por ejemplo dispositivos de administracion transdermica y/o para controlarlos |
KR20110082142A (ko) | 2008-10-06 | 2011-07-18 | 밀란 테크놀로지즈 인코포레이티드 | 비정질 로티고틴 경피 시스템 |
JP2012525943A (ja) | 2009-05-08 | 2012-10-25 | アイシス バイオポリマー,インク. | 改良された対電極を備えるイオントフォレシス装置 |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
MX2012007326A (es) | 2009-12-22 | 2012-08-01 | Lohmann Therapie Syst Lts | Polivinilpirrolidona para la estabilizacion de una dispersion solida de forma no cristalina de rotigotina. |
CN103228318B (zh) | 2010-11-23 | 2016-03-23 | 泰华制药国际有限公司 | 使用者激活的自包含共封装的离子透入给药系统 |
WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
WO2013075823A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising rotigotine and crystallization inhibitor |
DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
SG11201403162XA (en) | 2011-12-12 | 2014-10-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
TN2015000493A1 (en) | 2013-06-04 | 2017-04-06 | Lts Lohmann Therapie Systeme Ag | Transdermal delivery system |
-
2013
- 2013-10-30 TW TW102139313A patent/TW201431570A/zh unknown
- 2013-11-14 AR ARP130104186A patent/AR093481A1/es unknown
- 2013-11-21 AU AU2013350037A patent/AU2013350037B2/en not_active Ceased
- 2013-11-21 BR BR112015011729-5A patent/BR112015011729B1/pt active IP Right Grant
- 2013-11-21 CN CN201380054953.XA patent/CN104736146B9/zh active Active
- 2013-11-21 ES ES13795432.7T patent/ES2639294T3/es active Active
- 2013-11-21 EP EP13795432.7A patent/EP2922533B1/en not_active Revoked
- 2013-11-21 MX MX2015006357A patent/MX354502B/es active IP Right Grant
- 2013-11-21 JP JP2015543338A patent/JP6301356B2/ja active Active
- 2013-11-21 WO PCT/EP2013/003515 patent/WO2014079573A1/en active Application Filing
- 2013-11-21 CA CA2887085A patent/CA2887085C/en active Active
- 2013-11-21 US US14/443,210 patent/US11389410B2/en active Active
- 2013-11-21 IN IN2488DEN2015 patent/IN2015DN02488A/en unknown
- 2013-11-21 CN CN201910246426.8A patent/CN110200950B/zh active Active
- 2013-11-21 EA EA201500553A patent/EA201500553A1/ru unknown
- 2013-11-21 KR KR1020157008077A patent/KR20150094588A/ko not_active Application Discontinuation
-
2022
- 2022-01-31 US US17/589,262 patent/US20220151949A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104736146A (zh) | 2015-06-24 |
BR112015011729B1 (pt) | 2022-08-16 |
WO2014079573A1 (en) | 2014-05-30 |
CN104736146B9 (zh) | 2019-04-12 |
AU2013350037A1 (en) | 2015-06-11 |
CN110200950B (zh) | 2023-03-10 |
EP2922533B1 (en) | 2017-06-14 |
BR112015011729A2 (pt) | 2017-07-11 |
CA2887085C (en) | 2020-12-22 |
JP2016500086A (ja) | 2016-01-07 |
CN110200950A (zh) | 2019-09-06 |
TW201431570A (zh) | 2014-08-16 |
MX354502B (es) | 2018-03-08 |
CA2887085A1 (en) | 2014-05-30 |
JP6301356B2 (ja) | 2018-03-28 |
EP2922533A1 (en) | 2015-09-30 |
IN2015DN02488A (es) | 2015-09-11 |
CN104736146B (zh) | 2019-03-01 |
MX2015006357A (es) | 2016-02-10 |
US11389410B2 (en) | 2022-07-19 |
ES2639294T3 (es) | 2017-10-26 |
US20220151949A1 (en) | 2022-05-19 |
EA201500553A1 (ru) | 2015-12-30 |
US20150290142A1 (en) | 2015-10-15 |
KR20150094588A (ko) | 2015-08-19 |
AU2013350037B2 (en) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093481A1 (es) | Parche de varios dias para la administracion transdermica de rotigotina | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
JP2015534562A5 (es) | ||
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015010396A2 (pt) | terapia de combinação | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
BR112014010105A2 (pt) | aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv | |
IN2014DN09817A (es) | ||
BR112015025804A2 (pt) | derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida | |
MX2016008138A (es) | Sistema para el suministro transdermico de ingredientes activos. | |
BR112015014174A2 (pt) | composição de vacina para indivíduos virgens | |
CO7101247A2 (es) | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
PH12019502376A1 (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
CY1119793T1 (el) | Θεραπεια συνδυασμου σταθερων δοσεων της νοσου parkinson | |
BR112014015578A8 (pt) | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide | |
BRPI0620983B8 (pt) | uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico | |
BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
ECSP19024033A (es) | Composiciones de tesofensina | |
BR112014026776A2 (pt) | derivados de pirimidina para o tratamento de doenças bacterianas | |
BR112014026193A2 (pt) | uso intrauterino de 18-metil-15ß,16ß-metileno-19-nor-20-espirox-4-en-3-onas, sistemas intrauterinos contendo 18-metil-15ß,16ß-metileno-19-nor-20-espirox-4-en-3-onas, bem como o uso dos mesmos na contracepção e no tratamento ginecológico | |
CA3241241A1 (en) | Pharmaceutical composition for the treatment of infectious respiratory diseases caused by influenza and sars-cov-2, among others | |
CL2022001988A1 (es) | Sistema terapéutico transdérmico que comprende ingrediente rotigotina y adhesivo de silicona no resistente a mina | |
BR112022010127A2 (pt) | Compostos de arila e heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade de galatocerebrosidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |